Devonian Health Group Inc. is a Canadian, publicly-traded (TSXv:GSD ; OTCQB: DVHGF) clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs.
Devonian’s core strategy is to develop prescription drugs targeting multiple cellular targets and downregulating genes involved in inflammatory autoimmune diseases including, but not limited to, gastrointestinal, dermatological and hepatologic categories.
Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.
Devonian also operates a drug distribution division, Altius Healthcare Group LP, focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’.